2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2558

DNA Methylation-Dependent Regulation of Cathepsin E Gene Expression By the Transcription Factor Kaiso in MRL/Lpr Mice
Abstract Number: 2873

DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Abstract Number: 2947

Do Bone Marrow Lesions Reactivate Endochondral Ossification Leading to Osteophyte Genesis? Data from the Osteoarthritis Initiative
Abstract Number: 2891

Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases
Abstract Number: 986

Do Death Certificates Underestimate the Burden of Rare Diseases: The Example of Systemic Lupus Erythematosus Mortality in Sweden
Abstract Number: 927

Do Familiarity with Centers for Disease Control Guidelines, Continuing Education, and Provider Characteristics Influence Adherence to Chronic Pain Management Practices and Opioid Prescribing?
Abstract Number: 221

Do Immigrant Communities Play a Role in Total Knee Arthroplasty (TKA) Outcomes?
Abstract Number: 1800

Do Patient Reported Outcome Measurement Information System (PROMIS) Computer Adaptive Tests Correlate with Disease Activity in Juvenile Idiopathic Arthritis?
Abstract Number: 2557

Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?
Abstract Number: 444

Do Rheumatoid Arthritis Clinical Disease Activity Index Based Treat-to-Target Treatment Decisions Always Correspond to Usual Care Treatment Decisions at Point of Care?
Abstract Number: 1527

Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Abstract Number: 427

Do We Treat Men and Women Differently, and Is This a Good Thing?
Abstract Number: 697

Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Abstract Number: 2363

Does Galectin-3 Have Utility As a Biomarker of Subclinical Cardiovascular Disease in RA Patients Independently of RA Disease Activity?
Abstract Number: 2955

Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].